Abstract 3690
Background
With the success of immunotherapy in various solid cancers, the expression of programmed death-ligand 1 (PD-L1) in cancer cells has been attracting attention. The aim of this study was to analyze PD-L1 expression in resected UPS and evaluate its clinical impact.
Methods
All consecutive patients who were treated with UPS in Asan Medical Center, between January 1995 and December 2016, were retrospectively reviewed. PD-L1 staining was performed using SP263 antibody on their archived tissues. PD-L1 H-score was calculated by intensity (0-3) multiplied by proportion (0-100).
Results
A total of 176 patients with localized UPS who underwent curative-intent surgical resection were included in this study. There were 104 males (59.1%) and 72 females (40.9%), and the median age of patients was 59 years at the time of diagnosis. The most frequently involved primary site was extremities (84/176, 47.7%), followed by abdomen and pelvis (46/176, 26.1%), thorax (29/176, 16.5%), and head and neck (17/176, 9.7%). The PD-L1 analysis was available on slides from 114 (64.8%) patients and PD-L1 expression was observed in 83 (72.8%) cases. Intensity of staining varied between weak (44/83, 53.0%), intermediate (29/83, 34.9%), strong (10/83, 12.0%). Distribution of PD-L1 expression using different cut-off values were as follows: ≥1%: 83/114 (72.8%); ≥5%: 79/114 (69.3%); ≥10%: 52/114 (45.6%); ≥50%: 20/114 (17.5%). The 5-year disease free survival (DFS) rate seemed to be better in patients with PD-L1 positive than in patients with PD-L1 negative (56.5% vs 41.9%), but no statistical significant was observed (p = 0.183). There was a trend for better 5-year DFS rate with higher proportion of PD-L1 or higher PD-L1 H-score (proportion: 0% vs 1-49% vs ≥ 50, 41.9% vs 52.9% vs 70.1%, p = 0.098; H-score: 0 vs 1-100 vs ≥ 101, 41.9% vs 53.1% vs 75.7%, p = 0.087) without statistical singnificance.
Conclusions
In this study, PD-L1 protein expression was seen in substantial cases of resected UPS and it appeared to be a positive prognostic biomarker for longer DFS, although not statistically demonstrated. Further studies are needed comprehensively understand the impact of immune repertoire in UPS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract